Zynex Inc. develops, manufactures, markets, and sells non-invasive medical devices used for pain management, rehabilitation, and patient monitoring. Company updates have focused on financial results, payer and billing procedures, revenue and cash-flow performance, sales-force changes, and product activity in patient monitoring, including pulse oximetry.
Zynex news also covers governance and corporate-status developments, including board and leadership changes, compliance initiatives, strategic alternatives, and the company's court-supervised financial restructuring. Later regulatory disclosures document that the reorganization became effective and that the prior publicly traded common stock was cancelled.
Zynex, Inc. (NASDAQ: ZYXI), a medical technology company, reported a 37% increase in orders for Q2 2020 compared to Q2 2019, though orders were 23% lower than Q1 2020 due to COVID-19 impacts. The company updated its Q2 revenue estimate to between $18.9 million and $19.4 million, up from a previous estimate of $17.5 million to $18 million. Zynex also increased its full-year revenue estimate to between $80 million and $85 million, a projected increase of 76% to 87% over last year's revenue of $45.5 million.